Borderline Resectable Pancreatic Cancer
15 clinical trials · Condition
◉ Watch Borderline Resectable Pancreatic Cancer
| Record | Firm | Date |
|---|---|---|
| Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer (NCT04698915) | Galera Therapeutics, Inc. | 2021-05-07 |
| Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC (NCT04855331) | Fudan University | 2021-04-15 |
| IORT on Borderline Resectable Pancreatic Cancer (NCT04090463) | Universita di Verona | 2019-10-01 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer (NCT03850769) | Peking Union Medical College Hospital | 2019-05-01 |
| Divestment for Artery-involved Pancreatic Cancer (NCT03443921) | The First Affiliated Hospital with Nanjing Medical University | 2018-03-01 |
| Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer (NCT02717091) | Nagoya University | 2015-07-01 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer (NCT02241551) | Nathan Bahary, MD | 2014-12-01 |
Track Borderline Resectable Pancreatic Cancer automatically
Every clearance here is in the API, with alerts when new ones post.